Skip to main content
Premium Trial:

Request an Annual Quote

Alzheimer's Disease Test Firm DiamiR Awarded Additional $345K From NIA

NEW YORK — Diagnostics developer DiamiR said today that it has received an additional $345,000 in grant funding from the National Institute on Aging to develop a microRNA-based test for early-stage Alzheimer's disease.

In 2017, the Monmouth Junction, New Jersey-based company received a $2.8 million Phase IIB Small Business Innovation Research from the NIA for the test, called CogniMir. The new funding was awarded under that ongoing grant.

"Our novel diagnostic approach focuses on detecting changes in the plasma levels of microRNAs enriched in the specific brain regions affected by the disease," DiamiR CSO Samuil Umansky said in a statement. "Our goal is to provide drug developers and clinicians with a tool for identifying patients earlier, preferably before they exhibit clinical symptoms, when treatment can be more effective."

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.